{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T17:53:27Z","timestamp":1766512407896,"version":"3.48.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"DOI":"10.7759\/cureus.99942","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T17:50:25Z","timestamp":1766512225000},"source":"Crossref","is-referenced-by-count":0,"title":["Psychedelics as a Therapeutic Opportunity or Threat: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Pawe\u0142","family":"Liszka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata","family":"Og\u00f3rek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaudia M","family":"Olejnik-Chlewicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konrad","family":"Puchalski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Zasiad\u0142a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaudia M","family":"Patrzyk\u0105t","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Perediatkiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Urba\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142 M","family":"\u0141uczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Brodowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2021.12.009","article-title":"Psychedelics","volume":"32","author":"Kelmendi B","year":"2022","unstructured":"Kelmendi B, Kaye AP, Pittenger C, Kwan AC. Psychedelics. Curr Biol. 2022, 32:R63-7. 10.1016\/j.cub.2021.12.009","journal-title":"Curr Biol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols DE","year":"2016","unstructured":"Nichols DE. Psychedelics. Pharmacol Rev. 2016, 68:264-355. 10.1124\/pr.115.011478","journal-title":"Pharmacol Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/pcn5.146","article-title":"Ayahuasca: a review of historical, pharmacological, and therapeutic aspects","volume":"2","author":"Ruffell SG","year":"2023","unstructured":"Ruffell SG, Crosland-Wood M, Palmer R, et al.. Ayahuasca: a review of historical, pharmacological, and therapeutic aspects. PCN Rep. 2023, 2:e146. 10.1002\/pcn5.146","journal-title":"PCN Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X16666180125095902","article-title":"Ayahuasca: psychological and physiologic effects, pharmacology and potential uses in addiction and mental illness","volume":"17","author":"Hamill J","year":"2019","unstructured":"Hamill J, Hallak J, Dursun SM, Baker G. Ayahuasca: psychological and physiologic effects, pharmacology and potential uses in addiction and mental illness. Curr Neuropharmacol. 2019, 17:108-28. 10.2174\/1570159X16666180125095902","journal-title":"Curr Neuropharmacol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.724606","article-title":"Psychedelics and neuroplasticity: a systematic review unraveling the biological underpinnings of psychedelics","volume":"12","author":"de Vos CM","year":"2021","unstructured":"de Vos CM, Mason NL, Kuypers KP. Psychedelics and neuroplasticity: a systematic review unraveling the biological underpinnings of psychedelics. Front Psychiatry. 2021, 12:724606. 10.3389\/fpsyt.2021.724606","journal-title":"Front Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27082520","article-title":"Psychedelics: alternative and potential therapeutic options for treating mood and anxiety disorders","volume":"27","author":"Lowe H","year":"2022","unstructured":"Lowe H, Toyang N, Steele B, Grant J, Ali A, Gordon L, Ngwa W. Psychedelics: alternative and potential therapeutic options for treating mood and anxiety disorders. Molecules. 2022, 27:2520. 10.3390\/molecules27082520","journal-title":"Molecules"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1134454","article-title":"Therapeutic effect of psilocybin in addiction: a systematic review","volume":"14","author":"van der Meer PB","year":"2023","unstructured":"van der Meer PB, Fuentes JJ, Kaptein AA, et al.. Therapeutic effect of psilocybin in addiction: a systematic review. Front Psychiatry. 2023, 14:1134454. 10.3389\/fpsyt.2023.1134454","journal-title":"Front Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis AK","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, et al.. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021, 78:481-9. 10.1001\/jamapsychiatry.2020.3285","journal-title":"JAMA Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02565-4","article-title":"MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial","volume":"29","author":"Mitchell JM","year":"2023","unstructured":"Mitchell JM, Ot'alora G M, van der Kolk B, et al.. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med. 2023, 29:2473-80. 10.1038\/s41591-023-02565-4","journal-title":"Nat Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-022-06066-z","article-title":"Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants","volume":"239","author":"M\u00fcller F","year":"2022","unstructured":"M\u00fcller F, Kraus E, Holze F, et al.. Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants. Psychopharmacology (Berl). 2022, 239:1933-43. 10.1007\/s00213-022-06066-z","journal-title":"Psychopharmacology (Berl)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci8030047","article-title":"Hallucinogen Persisting Perception Disorder: etiology, clinical features, and therapeutic perspectives","volume":"8","author":"Martinotti G","year":"2018","unstructured":"Martinotti G, Santacroce R, Pettorruso M, et al.. Hallucinogen Persisting Perception Disorder: etiology, clinical features, and therapeutic perspectives. Brain Sci. 2018, 8:47. 10.3390\/brainsci8030047","journal-title":"Brain Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/02698811231211219","article-title":"Drug-drug interactions involving classic psychedelics: a systematic review","volume":"38","author":"Halman A","year":"2024","unstructured":"Halman A, Kong G, Sarris J, Perkins D. Drug-drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol. 2024, 38:3-18. 10.1177\/02698811231211219","journal-title":"J Psychopharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-022-01389-z","article-title":"Towards an understanding of psychedelic-induced neuroplasticity","volume":"48","author":"Calder AE","year":"2023","unstructured":"Calder AE, Hasler G. Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology. 2023, 48:104-12. 10.1038\/s41386-022-01389-z","journal-title":"Neuropsychopharmacology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2020.116980","article-title":"Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention","volume":"218","author":"Barrett FS","year":"2020","unstructured":"Barrett FS, Krimmel SR, Griffiths RR, Seminowicz DA, Mathur BN. Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention. Neuroimage. 2020, 218:116980. 10.1016\/j.neuroimage.2020.116980","journal-title":"Neuroimage"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2022.119220","article-title":"Serotonergic psychedelic drugs LSD and psilocybin reduce the hierarchical differentiation of unimodal and transmodal cortex","volume":"256","author":"Girn M","year":"2022","unstructured":"Girn M, Roseman L, Bernhardt B, Smallwood J, Carhart-Harris R, Nathan Spreng R. Serotonergic psychedelic drugs LSD and psilocybin reduce the hierarchical differentiation of unimodal and transmodal cortex. Neuroimage. 2022, 256:119220. 10.1016\/j.neuroimage.2022.119220","journal-title":"Neuroimage"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2021.06.008","article-title":"Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in\u00a0vivo","volume":"109","author":"Shao LX","year":"2021","unstructured":"Shao LX, Liao C, Gregg I, Davoudian PA, Savalia NK, Delagarza K, Kwan AC. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in\u00a0vivo. Neuron. 2021, 109:2535-44.e4. 10.1016\/j.neuron.2021.06.008","journal-title":"Neuron"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291715002901","article-title":"The paradoxical psychological effects of lysergic acid diethylamide (LSD)","volume":"46","author":"Carhart-Harris RL","year":"2016","unstructured":"Carhart-Harris RL, Kaelen M, Bolstridge M, et al.. The paradoxical psychological effects of lysergic acid diethylamide (LSD). Psychol Med. 2016, 46:1379-90. 10.1017\/S0033291715002901","journal-title":"Psychol Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2174\/1573413713666170619092629","article-title":"Dreams and psychedelics: neurophenomenological comparison and therapeutic implications","volume":"15","author":"Kraehenmann R","year":"2017","unstructured":"Kraehenmann R. Dreams and psychedelics: neurophenomenological comparison and therapeutic implications. Curr Neuropharmacol. 2017, 15:1032-42. 10.2174\/1573413713666170619092629","journal-title":"Curr Neuropharmacol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/0269881117731279","article-title":"Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors","volume":"32","author":"Griffiths RR","year":"2018","unstructured":"Griffiths RR, Johnson MW, Richards WA, et al.. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J Psychopharmacol. 2018, 32:49-69. 10.1177\/0269881117731279","journal-title":"J Psychopharmacol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1177\/02698811211069100","article-title":"Adverse effects of psychedelics: from anecdotes and misinformation to systematic science","volume":"36","author":"Schlag AK","year":"2022","unstructured":"Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ. Adverse effects of psychedelics: from anecdotes and misinformation to systematic science. J Psychopharmacol. 2022, 36:258-72. 10.1177\/02698811211069100","journal-title":"J Psychopharmacol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson MW","year":"2017","unstructured":"Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse. 2017, 43:55-60. 10.3109\/00952990.2016.1170135","journal-title":"Am J Drug Alcohol Abuse"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial","volume":"79","author":"Bogenschutz MP","year":"2022","unstructured":"Bogenschutz MP, Ross S, Bhatt S, et al.. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2022, 79:953-62. 10.1001\/jamapsychiatry.2022.2096","journal-title":"JAMA Psychiatry"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths RR","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, et al.. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016, 30:1181-97. 10.1177\/0269881116675513","journal-title":"J Psychopharmacol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2023.2281582","article-title":"Psychedelics for treatment resistant depression: are they game changers?","volume":"24","author":"Kalfas M","year":"2023","unstructured":"Kalfas M, Taylor RH, Tsapekos D, Young AH. Psychedelics for treatment resistant depression: are they game changers?. Expert Opin Pharmacother. 2023, 24:2117-32. 10.1080\/14656566.2023.2281582","journal-title":"Expert Opin Pharmacother"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyaa018","article-title":"Reviewing the potential of psychedelics for the treatment of PTSD","volume":"23","author":"Krediet E","year":"2020","unstructured":"Krediet E, Bostoen T, Breeksema J, van Schagen A, Passie T, Vermetten E. Reviewing the potential of psychedelics for the treatment of PTSD. Int J Neuropsychopharmacol. 2020, 23:385-400. 10.1093\/ijnp\/pyaa018","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102799","article-title":"Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial","volume":"76","author":"Erritzoe D","year":"2024","unstructured":"Erritzoe D, Barba T, Greenway KT, et al.. Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial. EClinicalMedicine. 2024, 76:102799. 10.1016\/j.eclinm.2024.102799","journal-title":"EClinicalMedicine"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1177\/02698811211073759","article-title":"Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up","volume":"36","author":"Gukasyan N","year":"2022","unstructured":"Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, Griffiths RR. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up. J Psychopharmacol. 2022, 36:151-8. 10.1177\/02698811211073759","journal-title":"J Psychopharmacol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291724002496","article-title":"Adverse psychiatric effects of psychedelic drugs: a systematic review of case reports","volume":"54","author":"Yildirim B","year":"2024","unstructured":"Yildirim B, Sahin SS, Gee A, et al.. Adverse psychiatric effects of psychedelic drugs: a systematic review of case reports. Psychol Med. 2024, 54:1-13. 10.1017\/S0033291724002496","journal-title":"Psychol Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-022-01297-2","article-title":"Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects","volume":"47","author":"Holze F","year":"2022","unstructured":"Holze F, Ley L, M\u00fcller F, et al.. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. 2022, 47:1180-7. 10.1038\/s41386-022-01297-2","journal-title":"Neuropsychopharmacology"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/HRP.0000000000000439","article-title":"Pharmacological treatment of Hallucinogen Persisting Perception Disorder (HPPD): a systematic review","volume":"33","author":"Neven A","year":"2025","unstructured":"Neven A, Blom JD. Pharmacological treatment of Hallucinogen Persisting Perception Disorder (HPPD): a systematic review. Harv Rev Psychiatry. 2025, 33:264-75. 10.1097\/HRP.0000000000000439","journal-title":"Harv Rev Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/443080-psychedelics-as-a-therapeutic-opportunity-or-threat-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T17:50:26Z","timestamp":1766512226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/443080-psychedelics-as-a-therapeutic-opportunity-or-threat-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.99942","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,23]]}}}